Penpulimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Penpulimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Penpulimab overview
Akeso overview
Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug research and development, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Penpulimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.